title: Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.
abstract: Population sequencing was performed for persons identified with persistent low-level viremia in 2 clinical trials. Persistent low-level viremia (defined as plasma HIV-1 RNA level >50 and <1000 copies/mL in at least 2 determinations over a 24-week period, after at least 24 weeks of antiretroviral therapy) was observed in 65 (5.6%) of 1158 patients at risk. New resistance mutations were detected during persistent low-level viremia in 37% of the 54 evaluable cases. The most common mutations were M184I/V (14 cases), K103N (9), and M230L (3). Detection of new mutations was associated with higher HIV-1 RNA levels during persistent low-level viremia.
authors.affiliation: Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA. b-taiwo@northwestern.edu
authors.forename: Babafemi
authors.initials: B
authors.lastname: Taiwo
authors.forename: Sebastien
authors.initials: S
authors.lastname: Gallien
authors.forename: Evgenia
authors.initials: E
authors.lastname: Aga
authors.forename: Heather
authors.initials: H
authors.lastname: Ribaudo
authors.forename: Richard
authors.initials: R
authors.lastname: Haubrich
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Kuritzkes
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Eron
mesh_terms: D000328:Adult; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008297:Male; D009154:Mutation; D012189:Retrospective Studies; D014766:Viremia / Q000097:blood / Q000821:virology*